Compare GEMI & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEMI | RLAY |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | GEMI | RLAY |
|---|---|---|
| Price | $8.64 | $10.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $14.50 | $14.50 |
| AVG Volume (30 Days) | 1.5M | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $21.99 | N/A |
| Revenue Next Year | $76.08 | $178.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $5.57 | $1.78 |
| 52 Week High | $34.67 | $11.43 |
| Indicator | GEMI | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 57.93 | 62.51 |
| Support Level | $5.57 | $2.99 |
| Resistance Level | $11.29 | $11.43 |
| Average True Range (ATR) | 0.63 | 0.67 |
| MACD | 0.46 | 0.04 |
| Stochastic Oscillator | 73.67 | 55.00 |
Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).